N/A
N=358
Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Bottom Line
View on ClinicalTrials.gov: NCT00941733 ↗Enrolled (actual)
358
Serious AEs
80.7%
Results posted
Oct 2014
Primary outcome: Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- IN.PACT Amphirion (Device); Standard PTA (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medtronic Endovascular
- Primary completion
- Aug 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) |
0.605; 0.616 | — |
| PRIMARY Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients |
9.2; 13.1 | — |
| PRIMARY Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR) |
17.67; 15.79 | — |
| SECONDARY Amputation Free Survival |
81.1; 89.2 | — |
| SECONDARY Rate of Wound Healing |
73.8; 76.9 | — |
| SECONDARY Amputation Free Survival and Wound Healing |
58.7; 68.0 | — |
| SECONDARY Amputation Free Survival and Resolved Critical Limb Ischemia (CLI) |
57.1; 66.0 | — |
| SECONDARY Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR) |
39.6; 34.2 | — |
| SECONDARY Primary Sustained Clinical Improvement |
69.3; 68.1 | — |
| SECONDARY Secondary Sustained Clinical Improvement |
73.6; 78.0 | — |
| SECONDARY Quality of Life Assessment by EQ5D |
0.6975; 0.7445 | — |
| SECONDARY Walking Capacity Assessment |
74.6; 75.4 | — |
| SECONDARY MAE (Major Adverse Events) |
35.2; 25.2 | — |
| SECONDARY Device Success |
98.0; 96.3 | — |
| SECONDARY Technical Success |
93.2; 88.4 | — |
| SECONDARY Procedural Success |
98.3; 100 | — |
| SECONDARY Days of Hospitalization |
4.5; 4.0 | — |
| SECONDARY Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA) |
82.0; 71.0 | — |
Summary
This is a prospective, multi-center, randomized (2:1) trial of symptomatic patients with critical limb ischemia (CLI) secondary to atherosclerotic lesions (stenotic or occluded) of the infrapopliteal vessels. Patients will undergo a percutaneous transluminal endovascular procedure with either the IN.PACT Amphirion™ drug eluting balloon or with a standard (Percutaneous Transluminal Angioplasty) PTA balloon. Patients will be followed with pre-study, post-study, and follow-up evaluations.
Eligibility Criteria
Inclusion Criteria
General Inclusion Criteria
- Age ≥18 years and ≤85 years
- Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an Ethical Committee approved consent form
- Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
- Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 4, 5 or 6
- Life expectancy >1 year in the Investigator's opinion
General Angiographic Inclusion Criteria
- Reference vessel(s) diameter between 2 and 4 mm
- Single or multiple lesions with ≥70% diameter stenosis (DS) of different lengths in one or more main afferent crural vessels including the tibioperoneal trunk
- At least one non occluded crural vessel with angiographically documented run-off to the foot either direct or through collaterals
Angiographic Inclusion Criteria for Late Lumen Loss (LLL) assessment
- Angio-target lesion (TL) is one identifiable single solitary or series of multiple adjacent lesions with a diameter stenosis (DS) ≥70% and a cumulative length ≤100 mm that can be covered by a single IN.PACT Amphirion™ (10 mm balloon landing zone in both edges is mandatory)
- Angio-target lesion (TL) is the only lesion in that vessel (only one Angio-TL per patient is allowed)
Exclusion Criteria
General Exclusion Criteria
- Patient unwilling or unlikely to comply with Follow-Up schedule
- Planned major index limb amputation
General Angiographic Exclusion Criteria
- Lesion and / or occlusions located or extending in the popliteal artery or below the ankle joint space
- Inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA), popliteal arteries with length ≥15 cm
- Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA) and popliteal arteries left untreated
- Previously implanted stent in the target lesions(s)
- Aneurysm in the target vessel
- Acute thrombus in the target limb
General Procedural Exclusion Criteria
- Failure to obtain a <30% residual stenosis in pre-existing, hemodynamically significant (≥50% diameter stenosis (DS) and <15 cm length) inflow lesions in the ipsilateral iliac, SFA and popliteal artery. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions.
- Failure to cross the TL with a 0.014" guide wire
- Use of alternative therapy, e.g. atherectomy, cutting balloon, laser, radiation therapy, DES as part of the index procedure
ANGIOGRAPHIC cohort General Exclusion Criteria:
- Glomerular Filtration Rate (GFR) <30 ml/min except for patients with renal end stage disease on chronic haemodialysis
Data sourced from ClinicalTrials.gov (NCT00941733). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.